AIDS-Related Kaposi's Sarcoma (ARKS) Therapeutics -Pipeline Assessment and Market Forecasts to 2017

AIDS-Related Kaposi’s Sarcoma (ARKS) Therapeutics -Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “AIDS-Related Kaposi’s Sarcoma (ARKS) Therapeutics -Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global AIDS Related Kaposi’s Sarcoma Therapeutics market. The report identifies the key trends shaping and driving the global AIDS Related Kaposi’s Sarcoma Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global AIDS Related Kaposi’s Sarcoma Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the AIDS Related Kaposi’s Sarcoma Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) AIDS Related Kaposi’s Sarcoma Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries AIDS Related Kaposi’s Sarcoma Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the AIDS Related Kaposi’s Sarcoma Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in AIDS Related Kaposi’s Sarcoma Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AIDS Related Kaposi’s Sarcoma Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global AIDS Related Kaposi’s Sarcoma Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global AIDS Related Kaposi’s Sarcoma Therapeutics market landscape? – Identify, understand and capitalize.

1
1
1.1 List of Tables
1.2 List of Figures
2 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Introduction
2.1 Overview
2.2 Epidemiology
2.3 Symptoms
2.4 Pathogenesis of ARKS
2.5 Staging of ARKS
2.6 Diagnosis of ARKS
2.7 Treatment of ARKS
2.7.1 Local Treatment
2.7.2 Cytotoxic Chemotherapy
2.7.3 Molecular Targeted Therapy
2.7.4 HAART (Highly Active Antiretroviral Treatment)
2.8 Pipeline Report Guidance
3 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Market Characterization
3.1 ARKS Therapeutics Market Size (2005–2010) – Global
3.2 ARKS Therapeutics Market Forecast (2010–2017) – Global
3.3 ARKS Therapeutics Market Size (2005–2010) – The US
3.4 ARKS Therapeutics Market Forecast (2010–2017) – The US
3.5 ARKS Therapeutics Market Size (2005–2010) – France
3.6 ARKS Therapeutics Market Forecast (2010–2017) – France
3.7 ARKS Therapeutics Market Size (2005–2010) – Germany
3.8 ARKS Therapeutics Market Forecast (2010–2017) – Germany
3.9 ARKS Therapeutics Market Size (2005–2010) – Italy
3.10 ARKS Therapeutics Market Forecast (2010–2017) – Italy
3.11 ARKS Therapeutics Market Size (2005–2010) – Spain
3.12 ARKS Therapeutics Market Forecast (2010–2017) – Spain
3.13 ARKS Therapeutics Market Size (2005–2010) – The UK
3.14 ARKS Therapeutics Market Forecast (2010–2017) – The UK
3.15 ARKS Therapeutics Market Size (2005–2010) – Japan
3.16 ARKS Therapeutics Market Forecast (2010–2017) – Japan
3.17 Drivers and Barriers for the ARKS Therapeutics Market
3.17.1 Barriers for the ARKS Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for Major Marketed Products in the ARKS Therapeutics Market
4.3.1 Doxil
4.3.2 Daunorubicin
4.3.3 Paclitaxel
4.3.4 Panretin (alitretinoin)
4.4 Key Takeaway
5 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 ARKS Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 ARKS Therapeutics – Phase II Pipeline
5.3.2 ARKS Therapeutics – Phase I Pipeline
5.3.3 ARKS Therapeutics – Preclinical Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 ARKS Therapeutics – Pipeline by Mechanism of Action
5.5 Key Takeaway
6 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in ARKS Therapeutics Clinical Trials
7 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Strategic Assessment
7.1 ARKS Therapeutics: Implications for Future Market Competition
8 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 PTC Therapeutics, Inc.
8.2.2 Aphios Corporation
9 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Licensing and Partnership Deals
10 AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Prevalence of Kaposi’s Sarcoma in HIV Patients, Top Seven Markets, 2010
Table 2: AIDS Clinical Trials Group Staging Classification for ARKS, 2011
Table 3: ARKS Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 4: ARKS Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 5: ARKS Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 6: ARKS Therapeutics Market, The US, Forecast ($m), 2010–2017
Table 7: ARKS Therapeutics Market, France, Revenue ($’000), 2005–2010
Table 8: ARKS Therapeutics Market, France, Forecast ($’000), 2010–2017
Table 9: ARKS Therapeutics Market, Germany, Revenue ($’000), 2005–2010
Table 10: ARKS Therapeutics Market, Germany, Forecast ($’000), 2010–2017
Table 11: ARKS Therapeutics Market, Italy, Revenue ($’000), 2005–2010
Table 12: ARKS Therapeutics Market, Italy, Forecast ($’000), 2010–2017
Table 13: ARKS Therapeutics Market, Spain, Revenue ($’000), 2005–2010
Table 14: ARKS Therapeutics Market, Spain, Forecast ($’000), 2010–2017
Table 15: ARKS Therapeutics Market, The UK, Revenue ($’000), 2005–2010
Table 16: ARKS Therapeutics Market, The UK, Forecast ($’000), 2010–2017
Table 17: ARKS Therapeutics Market, Japan, Revenue ($’000), 2005–2010
Table 18: ARKS Therapeutics Market, Japan, Forecast ($’000), 2010–2017
Table 19: Response in Patients with Refractory AIDS-related Kaposi’s Sarcoma
Table 20: Panretin Clinical Study Response
Table 21: ARKS Therapeutics – Phase II Pipeline, 2011
Table 22: ARKS Therapeutics – Phase I Pipeline, 2011
Table 23: ARKS Therapeutics – Preclinical Pipeline, 2011
Table 24: ARKS Therapeutics – Clinical Trials by Country, 2011
Table 25: ARKS Therapeutics - Clinical Trials by Phase, 2011
Table 26: ARKS Therapeutics - Clinical Trials by Status, 2011
Table 27: ARKS Therapeutics - Prominent Sponsors, 2011
Table 28: ARKS Therapeutics – Companies and Institutions Participating in Clinical Trials, 2011
Table 29: PTC Therapeutics, Pipeline Products, 2011
Table 30: PTC Therapeutics, Deals, 2009-2011
Table 31: Aphios Corporation, Pipeline Products, 2011
Table 32: Aphios Corporation, Deals, 2009-2011
Table 33: ARKS Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Etiology of KS
Figure 2: ARKS Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 3: ARKS Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 4: ARKS Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 5: ARKS Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 6: ARKS Therapeutics Market, France, Revenue ($’000), 2005–2010
Figure 7: ARKS Therapeutics Market, France, Forecast ($’000), 2010–2017
Figure 8: ARKS Therapeutics Market, Germany, Revenue ($’000), 2005–2010
Figure 9: ARKS Therapeutics Market, Germany, Forecast ($’000), 2010–2017
Figure 10: ARKS Therapeutics Market, Italy, Revenue ($’000), 2005–2010
Figure 11: ARKS Therapeutics Market, Italy, Forecast ($’000), 2010–2017
Figure 12: ARKS Therapeutics Market, Spain, Revenue ($’000), 2005–2010
Figure 13: ARKS Therapeutics Market, Spain, Forecast ($’000), 2010–2017
Figure 14: ARKS Therapeutics Market, The UK, Revenue ($’000), 2005–2010
Figure 15: ARKS Therapeutics Market, The UK, Forecast ($’000), 2010–2017
Figure 16: ARKS Therapeutics Market, Japan, Revenue ($’000), 2005–2010
Figure 17: ARKS Therapeutics Market, Japan, Forecast ($’000), 2010–2017
Figure 18: ARKS Therapeutics Market, Drivers and Barriers, 2010
Figure 19: Opportunity and Unmet Need in the ARKS Therapeutics Market, 2010
Figure 20: ARKS Therapeutics – Strategic Competitor Assessment, 2010
Figure 21: ARKS Therapeutics – Pipeline by Phase of Development, (%), 2010
Figure 22: ARKS Therapeutics – Technology Trends Analytic Framework, 2011
Figure 23: ARKS Therapeutics – Technology Trends Analytic Framework – Description, 2011
Figure 24: ARKS Therapeutics – Pipeline by Mechanism of Action, (%), 2011
Figure 25: ARKS Therapeutics – Clinical Trials by Country, 2011
Figure 26: ARKS Therapeutics – Clinical Trials by Phase, (%), 2011
Figure 27: ARKS Therapeutics - Clinical Trials by Status, (%), 2011
Figure 28: ARKS Therapeutics - Overall Sponsors, (%), 2011
Figure 29: ARKS Therapeutics - Sponsors, (%), 2011
Figure 30: ARKS Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 31: Implications for Future Market Competition in the ARKS Therapeutics Market, 2010
Figure 32: ARKS Therapeutics – Pipeline by Company, 2010
Figure 33: Market Forecasting Model

GlobalData has released its new report, “AIDS-related Kaposi’s Sarcoma (ARKS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ARKS market. The report identifies the key trends shaping and driving the global ARKS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ARKS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Decreasing HIV Incidence and Doxil’s Patent Expiry Set to Erode Revenue and Cause Market Decline

GlobalData estimates that the global ARKS therapeutics market valued $13.1m in 2010, and is forecast to decline at a Compound Annual Growth Rate (CAGR) of 5% over the next seven years, to value $9.4m by 2017. This decline in growth is primarily attributed to the impending patent expiry of Doxil (liposomal doxorubicin), declining HIV incidence and weak pipeline activity. The advent of HAART (Highly Active Antiretroviral Treatment) therapy coupled with antiangiogenics has enabled the effective management of ARKS and prolonged the life-expectancy of HIV patients.

Weak Pipeline Fails to Uncover New Therapeutic Options

GlobalData’s research indicates that the ARKS pipeline is weak with no molecules in late stage (Phase III) clinical development. Phase II has seven first-in-class products such as tyrosine kinase inhibitors, VEGF (Vascular Endothelial Growth Factor) inhibitors and matrix metalloproteinases inhibitors. These products are being investigated in the middle stage and are expected to take approximately seven years to reach the regulatory filing stage. Any novel pipeline product which can cater to current high unmet need is expected to gain market acceptance.

High Unmet Need is Result of Prevailing Adverse Events

The unmet need in the ARKS therapeutics market is high, largely due to severe adverse events such as myelosuppression presented by current market products. Currently, Doxil is the only available product which is anticipated to go off-patent by 2014. There is high demand for a therapeutic agent which could effectively treat the disease without compromising the safety of the patient.

PTC Therapeutics, Inc.
Aphios Corporation

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.